- Neurodon has recently become a Member of the Longevity Biotechnology Association, a global non-profit organization aimed at identifying aging pathways that can be targeted therapeutically to extend lifespan and health. Neurodon joins a group of leading biotech and pharmaceutical companies, investors, and researchers interested in investigating the primary drivers of aging and age-related diseases.
There is a growing body of evidence that aberrant cellular calcium homeostasis, ER stress, and the UPR are correlated with aging and age-associated diseases such as neurodegeneration. Since Neurodon’s focus is on correcting this dysfunction, we envision leveraging our insight and small molecules to target aging both in a disease-focused and global manner. By partnering with the LBA, we will join like minded companies, researchers, and investors to generate new medicines to extend lifespan and improve health in the aging population.
Read more about the LBA here.
Read comments from the LBA about Neurodon joining here.
